Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Figures corrected NBB
Corrected annual account filed for 2023.
Financials
Financial year 2025
MEDIPHARM from Evere, company number BE0859994080, closed financial year 2025 with a result of € 843 after tax. For that financial year MEDIPHARM recorded a gross margin of € 253,182 and equity of € 336,778. Compared with financial year 2024, the result moved from € 46,117 to € 843. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 23, 2026.
€ 336,778
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 843
▼ 98% vs 2024
Profit after tax over the fiscal year.
€ 40,691
▼ 41% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 318,178.
People and assets in 2025
€ 210,523
▲ 29% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 28,599
▼ 39% vs 2024
Of which on lease € 10,124.
Debts at end 2025
€ 37,770
▼ 63% vs 2024
€ 24,041 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 137,159
▼ 5% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 15,674
▼ 59% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 316,028 | € 275,604 | € 278,783 | € 253,182 | ▼ 9% |
| Profit after taxes | € 19,662 | € 7,462 | € 46,117 | € 843 | ▼ 98% |
| Equity | € 282,356 | € 289,818 | € 335,935 | € 336,778 | |
| Total debts | € 468,614 | € 382,343 | € 311,741 | € 246,254 | ▼ 21% |
| Cash | € 68,350 | € 78,057 | € 69,449 | € 40,691 | ▼ 41% |
| Land & buildings | € 127,458 | € 123,970 | € 119,322 | € 114,672 | ▼ 4% |
| Retained profit | € 263,756 | € 271,218 | € 317,335 | € 318,178 | |
| Bank debt | € 104,726 | € 129,916 | € 101,040 | € 37,770 | ▼ 63% |
| Balance sheet total | € 750,970 | € 672,161 | € 647,676 | € 583,033 | ▼ 10% |
Key figures of MEDIPHARM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to MEDIPHARM?
What happened at MEDIPHARM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 843 (▼ 98% vs 2024). Source: NBB ↗
- SAMER CHEAIB became a director. NBB
- New establishment in Anderlecht. KBO
- New establishment in Schaarbeek. KBO
- Start of the company according to the CBE. KBO
In short
From € 19,662 profit in 2022 to € 843 profit in 2025.
Paid € 48,731 in corporate taxes since 2022.
Best year ever: 2024, with € 46,117 profit.
A new publication or filing at MEDIPHARM? We notify you, reason included.
Follow MEDIPHARMDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind MEDIPHARM is SAMER CHEAIB. SAMER CHEAIB is also behind MEDIPHARM ANDERLECHT and PHARMACIE HAYAT.
Directors
According to the 2025 annual accounts
since 2024
Establishments
Establishment units
Physical locations of this company
Provencewandelwegen 40
1140 Evere
Brabantstraat 162
1030 Schaarbeek
Active since 7 August 2003
Onderwijsstraat 115
1070 Anderlecht
Active since 1 February 2019
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0859.994.080
- VAT number
- BE 0859.994.080
- Registered office
- Provencewandelwegen 40, 1140 Evere
- Names & denominations
- MEDIPHARM
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 7 August 2003
- Peppol
- Active · Active since 5 Dec 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers